Trastuzumab resistance is common in patients with HER2-positive breast cancer who receive adjuvant therapy, with a 1-year recurrence of nearly 15% and a 10-year recurrence over 31% after trastuzumab-based therapy in HERA trial7. Here, ERBB2 is linked to breast carcinoma.